


GAU 1647

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 15270J-004740US
Client Reference No.: 209-US-CIP5

Assistant Commissioner for Patents
Washington, D.C. 20231



On January 4, 2001

RECEIVED

TOWNSEND and TOWNSEND and CREW LLP

By: Ch Fitting

JAN 12 2001

TECH CENTER 1600/2900

#15
1.97
1/16/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Schenk, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Search/Examination report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and

no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

RECEIVED

JAN 12 2001

TECH CENTER 1600/2900

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf

#15

FORM PTO-1449 (Modified)		Attorney Docket No.: 15270J-004740US		Application No.: 09/322,289	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Schenk, Dale B.			
		Filing Date: May 28, 1999		Group: 1647	
Reference Designation		U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class Filing Date (If Appropriate)
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Sub-class Translation (If Appropriate)
<u>AA</u>	EP 613 007	8/31/94	Europe		
<u>AB</u>	WO 95/11994	5/4/95	PCT		
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					TECH CENTER 1600/2000
<u>AC</u>	Schenk et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).				
<u>AD</u>	Van Gool et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994).				
EXAMINER	<u>SDumer</u>		DATE CONSIDERED	<u>6-13-01</u>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.